Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 16 02:17PM ET
12.01
Dollar change
+0.12
Percentage change
1.01
%
IndexRUT P/E- EPS (ttm)-1.89 Insider Own21.21% Shs Outstand256.14M Perf Week-9.15%
Market Cap3.35B Forward P/E- EPS next Y-0.76 Insider Trans9.79% Shs Float220.07M Perf Month-13.66%
Income-444.04M PEG- EPS next Q-0.42 Inst Own67.23% Short Float21.07% Perf Quarter43.49%
Sales1.19M P/S2818.92 EPS this Y30.65% Inst Trans-1.92% Short Ratio5.02 Perf Half Y230.85%
Book/sh2.28 P/B5.26 EPS next Y41.97% ROA-61.49% Short Interest46.38M Perf Year112.94%
Cash/sh1.00 P/C11.99 EPS next 5Y- ROE-81.91% 52W Range3.21 - 18.33 Perf YTD47.72%
Dividend Est.- P/FCF- EPS past 5Y-8.25% ROI-68.03% 52W High-34.48% Beta0.64
Dividend TTM- Quick Ratio2.70 Sales past 5Y0.00% Gross Margin-3091.17% 52W Low274.14% ATR (14)0.90
Dividend Ex-Date- Current Ratio2.79 EPS Y/Y TTM23.77% Oper. Margin-38734.99% RSI (14)37.97 Volatility5.90% 6.06%
Employees557 Debt/Eq0.13 Sales Y/Y TTM- Profit Margin-37345.42% Recom1.29 Target Price26.00
Option/ShortYes / Yes LT Debt/Eq0.12 EPS Q/Q28.86% Payout- Rel Volume0.43 Prev Close11.89
Sales Surprise-66.55% EPS Surprise-4.46% Sales Q/Q- EarningsFeb 28 AMC Avg Volume9.24M Price12.01
SMA20-13.02% SMA50-10.78% SMA20049.15% Trades Volume2,975,192 Change1.01%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Initiated Goldman Buy $12
Sep-18-23Reiterated Barclays Overweight $40 → $18
May-30-23Upgrade Wells Fargo Equal Weight → Overweight $11 → $17
Mar-27-23Resumed Wells Fargo Equal Weight $11
Jan-27-23Upgrade Piper Sandler Neutral → Overweight $11 → $14
Dec-09-22Downgrade Goldman Buy → Neutral $20 → $6
Oct-31-22Initiated Guggenheim Neutral
Aug-18-22Resumed Wells Fargo Equal Weight $14
Jan-28-22Upgrade Stifel Hold → Buy $23 → $25
Dec-07-21Resumed Cowen Outperform
Apr-08-24 01:51PM
Apr-05-24 05:03AM
Mar-29-24 11:30AM
Mar-26-24 04:11AM
Mar-23-24 09:00AM
05:30PM Loading…
Mar-22-24 05:30PM
Mar-18-24 08:01PM
02:00AM
Mar-15-24 08:18AM
Mar-07-24 06:01AM
Mar-06-24 04:42AM
Mar-05-24 01:00PM
Mar-04-24 06:30AM
Mar-02-24 06:50AM
Mar-01-24 05:00PM
05:47PM Loading…
Feb-29-24 05:47PM
12:17PM
10:37AM
09:44AM
05:51AM
Feb-28-24 05:35PM
04:42PM
04:35PM
04:01PM
Feb-27-24 08:52AM
Feb-26-24 05:39AM
Feb-25-24 08:07AM
05:01AM
Feb-23-24 06:14AM
Feb-22-24 08:45AM
04:00AM Loading…
04:00AM
Feb-20-24 03:38PM
11:02AM
08:00AM
06:30AM
Feb-19-24 08:36AM
Feb-16-24 05:30PM
04:04PM
03:38PM
03:35PM
03:19PM
Feb-12-24 07:14AM
Feb-08-24 07:27AM
Feb-07-24 05:10AM
Feb-05-24 05:25AM
Feb-04-24 06:27AM
Jan-19-24 05:15PM
Jan-15-24 12:27PM
Jan-08-24 05:31AM
Dec-28-23 05:59PM
11:13AM
08:01AM
Dec-27-23 05:26PM
02:02PM
12:21PM
12:21PM
11:21AM
10:41AM
09:57AM
07:06AM
07:00AM
Dec-22-23 05:15PM
Dec-18-23 02:58PM
Dec-12-23 08:45AM
05:29AM
Dec-07-23 11:31AM
Nov-20-23 12:00PM
Nov-17-23 05:00PM
Nov-08-23 05:04PM
01:03PM
07:55AM
Nov-07-23 04:26PM
04:01PM
Oct-31-23 04:01PM
09:05AM
Oct-24-23 06:54AM
Oct-20-23 05:15PM
Oct-16-23 08:15AM
Sep-27-23 04:01PM
Sep-22-23 06:25PM
Sep-15-23 04:20PM
07:26AM
Sep-14-23 06:10PM
04:36PM
Sep-07-23 11:30AM
07:31AM
Aug-31-23 10:16PM
Aug-28-23 11:53PM
Aug-18-23 05:00PM
Aug-09-23 11:14AM
Aug-08-23 05:50PM
04:50PM
04:01PM
Jul-31-23 06:10AM
Jul-25-23 04:01PM
Jul-24-23 04:01PM
Jul-21-23 05:34PM
Jul-13-23 04:01PM
Jul-11-23 04:30PM
11:18AM
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerMar 04 '24Option Exercise0.0015,623049,230Mar 06 06:20 PM
Vogt Frederick GInterim CEO & General CounselMar 04 '24Option Exercise0.0041,6620140,800Mar 06 06:19 PM
Rothbaum Wayne P.DirectorFeb 20 '24Buy9.155,000,00045,750,00028,067,333Feb 20 04:11 PM
MCPEAK MERRILL ADirectorFeb 20 '24Buy9.15250,0002,287,500320,150Feb 20 07:52 PM
Dukes Iain D.DirectorFeb 20 '24Buy9.1532,000292,80054,000Feb 20 04:21 PM
Vogt Frederick GInterim CEO & General CounselJan 16 '24Option Exercise0.0020,8340105,668Jan 18 06:09 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJan 16 '24Option Exercise0.002,813035,184Jan 18 06:09 PM
BILINSKY IGORChief Operating OfficerJan 16 '24Option Exercise0.002,813031,444Jan 18 06:07 PM
Vogt Frederick GInterim CEO & General CounselOct 16 '23Option Exercise0.0020,835093,685Oct 18 08:05 PM
BILINSKY IGORChief Operating OfficerOct 16 '23Option Exercise0.002,813030,026Oct 18 08:04 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerOct 16 '23Option Exercise0.002,813033,766Oct 18 08:03 PM
MCPEAK MERRILL ADirectorSep 18 '23Buy5.5610,00055,600248,633Sep 19 04:30 PM
Rothbaum Wayne P.DirectorSep 15 '23Buy5.305,000,00026,500,00023,067,333Sep 15 06:12 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJul 14 '23Option Exercise0.002,813032,348Jul 17 06:22 PM
Vogt Frederick GInterim CEO & General CounselJul 14 '23Option Exercise0.0020,834081,701Jul 17 06:22 PM
BILINSKY IGORChief Operating OfficerJul 14 '23Option Exercise0.002,813028,608Jul 17 06:21 PM